Clinical Trial Update: EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

View source ↗

Summary

A multicenter compassionate-use program of daclatasvir plus sofosbuvir, with or without ribavirin, for chronic hepatitis C is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Hepatitis C | Status: NO_LONGER_AVAILABLE